leisure time -WSS

leisure time

author：comprehensive 2025-09-29 22:52:01 - browse：52

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： UnitedHealth’s board chair also owns a personal investment firm

WSS

FDA gives detailed accounting of AI

Solve the antibiotic resistance crisis with preventive drugs

FDA's Pazdur wants cancer trials to range beyond China alone

Impact of Dobbs ruling felt at reproductive medicine meeting

Researchers explore possible ties between long Covid, menopause

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

leisure time

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Drug repurposing or repositioning? The language matters

Senate committee scrutinizes Medicare Advantage brokers

How to save PrEP access — and even expand it

FDA gives detailed accounting of AI

Anesthesiologist group: stop taking Ozempic before surgery

STAT Summit: Michael J. Fox on progress in Parkinson's research

explore

Impact of Dobbs ruling felt at reproductive medicine meeting

FDA gives detailed accounting of AI

Kaiser's Risant Health gobbled up Geisinger. Who is next?

NIH confirmation hearing shows politicization of research

BMI, flaws aside, is found to be useful estimate of body fat in youth

How climate

Wikipedia

hotspot

hotspot

hotspot